HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

anaplastic lymphoma kinase

Subscribe to New Research on anaplastic lymphoma kinase

GenBank AB073169 (rat); RefSeq NM_004304 (human); NM_007439 (mouse)

Also Known As:

ALK protein, human; ALK tyrosine kinase receptor precursor protein, human; Alk protein, mouse; Alk protein, rat; CD246 antigen, human; CD246 antigen, mouse; CD246 protein, human; CD246 protein, mouse; Tcrz protein, mouse; anaplastic lymphoma kinase Ki-1, human; anaplastic lymphoma kinase, human; anaplastic lymphoma kinase, mouse; anaplastic lymphoma kinase, rat

Networked: 1167 relevant articles (28 outcomes, 81 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes
- Enzymes: 34502
  - Transferases: 4296
    - Phosphotransferases: 30637
      - Phosphotransferases (Alcohol Group Acceptor)
        Protein Kinases: 9706
        Protein-Tyrosine Kinases: 12167
        anaplastic lymphoma kinase: 1167

Experts

1.	Medeiros, L Jeffrey: 31 articles (11/2014 - 09/2002)
2.	Inghirami, Giorgio: 25 articles (12/2015 - 02/2002)
3.	Shaw, Alice T: 23 articles (09/2015 - 10/2010)
4.	Rassidakis, George Z: 23 articles (11/2014 - 09/2002)
5.	Lai, Raymond: 23 articles (04/2013 - 09/2002)
6.	Chiarle, Roberto: 20 articles (12/2015 - 02/2002)
7.	Camidge, D Ross: 17 articles (10/2015 - 12/2009)
8.	Amin, Hesham M: 16 articles (09/2015 - 08/2003)
9.	Ou, Sai-Hong Ignatius: 15 articles (01/2016 - 01/2011)
10.	Takeuchi, Kengo: 15 articles (01/2015 - 01/2008)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/01/2013 - "Patients with non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK) gene rearrangements may be treated successfully with the ALK inhibitor crizotinib. " 06/01/2015 - "Crizotinib has been reported to be particularly effective and to have acceptable toxicity in advanced anaplastic lymphoma kinase (ALK)-positive, non-small cell lung cancer (NSCLC). " 10/20/2015 - "The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer. " 06/01/2015 - "Based on the literature findings, recent studies estimate thatapproximately 50-60% of patients with non small cell lung cancer(NSCLC) harbor at list one activated pathway with the most commonmutations being in the Kirsten ras (KRAS) gene (24%) and theepidermal growth factor receptor (EGFR) gene (13-22%), with translocations involving anaplastic lymphoma kinase (ALK) in another5-6% (1, 2). " 12/01/2014 - "Alectinib/CH5424802 is a known inhibitor of anaplastic lymphoma kinase (ALK) and is being evaluated in clinical trials for the treatment of ALK fusion-positive non-small cell lung cancer (NSCLC). "
2.	Lung Neoplasms (Lung Cancer) 01/01/2015 - "Because anaplastic lymphoma kinase (ALK) is dependent on Hsp90 for protein stability, Hsp90 inhibitors are effective in controlling growth of lung cancer cells with ALK rearrangement. " 12/01/2011 - "EML4-ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. " 09/01/2014 - "Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer." 01/01/2016 - "Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer." 11/01/2015 - "Accurate assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small-cell lung cancers (NSCLCs) is critical to identify patients who are likely to respond to crizotinib. "
3.	Neoplasms (Cancer) 01/01/2012 - "The promising results of anaplastic lymphoma kinase (ALK) inhibitors have changed the significance of ALK fusions in several types of cancer. " 04/01/2015 - "•Inflammatory myofibroblastic tumor (IMT) tends to locally recur but rarely metastasizes.•IMT tends to locally recur but rarely metastasizes.•IMTs that do not express anaplastic lymphoma kinase (ALK) have worse prognosis.•Current trials for ALK targeted therapies show promise in treating this neoplasm. " 09/01/2015 - "Using the national clinical trials network (NCTN) of the National Cancer Institute (NCI), several thousand patients with operable NSCLC will undergo tumor genotyping for EGFR mutations or rearrangement of anaplastic lymphoma kinase (ALK). " 08/01/2015 - "Anaplastic lymphoma kinase gene expression in small round cell tumors of childhood--a comparative ımmunohistochemical study." 03/01/2011 - "Immunohistochemical study showed that tumor cells stained positive with CD30, EMA and CD4, and negative for CD3, CD8, CD5, CD20, CD79a, CD138 and anaplastic lymphoma kinase 1 (ALK or Ki-1)."
4.	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/01/2012 - "Apart from anaplastic lymphoma kinase-positive anaplastic large cell lymphoma, that have a good outcome, other nodal and extranodal forms have a 5-year overall survival of about 30%. " 02/01/2013 - " Patients with anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK+-ALCL) were excluded from this study. " 07/01/2009 - "Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma has a significantly better prognosis than anaplastic lymphoma kinase-negative anaplastic large cell lymphoma and molecular studies have illustrated that each entity has a distinct molecular profile. " 06/01/2008 - "The aim of this study was to investigate the expression of anaplastic lymphoma kinase (ALK) protein resulted from chromosome translocation in anaplastic large cell lymphoma (ALCL) and its relationship with the age and prognosis of patients with ALCL. " 09/01/2005 - "In previous studies of anaplastic large cell lymphoma (ALCL), we showed that inhibition of Jak3 down-regulates activated/phosphorylated Stat3 (pStat3), decreases anaplastic lymphoma kinase (ALK) enzymatic activity, and induces cell-cycle arrest and apoptosis in ALK-positive ALCL. "
5.	Lymphoma (Lymphomas) 02/01/2005 - "The purpose of this study was to evaluate fluorescence in situ hybridization abnormalities of the 2p23 anaplastic lymphoma kinase (ALK) gene loci in lymphomas with anaplastic morphology. " 01/01/2015 - "The year 2014 marked the 20th anniversary of this seminal publication by Steve Morris et al. The discovery of anaplastic lymphoma kinase (ALK) has allowed the definition of a distinct entity within the clinically and pathologically heterogeneous group of CD30+ lymphomas. " 02/01/2014 - "Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients." 10/01/2013 - "This included 30 cases of anaplastic lymphoma kinase+ (ALK+), ALCL and 20 cases of anaplastic lymphoma kinase- (ALK-), ALCL. " 07/01/2013 - "Anaplastic lymphoma kinase (ALK) and MYC are oncogenes often dysregulated in pediatric lymphomas. "

Related Drugs and Biologics

1.	Epidermal Growth Factor Receptor (EGF Receptor)
2.	Protein-Tyrosine Kinases (Tyrosine Kinase)
3.	pemetrexed (MTA)
4.	Phosphotransferases (Kinase)
5.	Adenocarcinoma of lung
6.	Platinum
7.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
8.	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)
9.	Brefeldin A
10.	nucleophosmin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Thoracotomy
5.	Breast Implants (Breast Implant)